Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1953 5
1954 6
1955 13
1956 26
1957 24
1958 29
1959 26
1960 24
1961 30
1962 34
1963 62
1964 89
1965 48
1966 54
1967 47
1968 67
1969 78
1970 80
1971 75
1972 68
1973 82
1974 81
1975 86
1976 63
1977 50
1978 64
1979 54
1980 63
1981 56
1982 55
1983 55
1984 65
1985 69
1986 63
1987 78
1988 85
1989 111
1990 99
1991 114
1992 113
1993 135
1994 116
1995 120
1996 158
1997 116
1998 141
1999 136
2000 154
2001 139
2002 157
2003 184
2004 165
2005 170
2006 165
2007 164
2008 143
2009 152
2010 164
2011 192
2012 185
2013 202
2014 220
2015 245
2016 243
2017 217
2018 241
2019 258
2020 274
2021 254
2022 244
2023 223
2024 145

Text availability

Article attribute

Article type

Publication date

Search Results

7,538 results

Results by year

Filters applied: . Clear all
Page 1
Busulfan.
Buggia I, Locatelli F, Regazzi MB, Zecca M. Buggia I, et al. Ann Pharmacother. 1994 Sep;28(9):1055-62. doi: 10.1177/106002809402800911. Ann Pharmacother. 1994. PMID: 7803883 Review.
Pharmacokinetics of high-dose busulfan are age-dependent. Busulfan systemic exposure and, thus, tissue and tumor exposure are lower in children than with adults. ...At higher dosages, busulfan is a fundamental part of myeloablative therapies for patients unde …
Pharmacokinetics of high-dose busulfan are age-dependent. Busulfan systemic exposure and, thus, tissue and tumor exposure are …
Busulfan.
O'Marcaigh AS, Betcher DL. O'Marcaigh AS, et al. J Pediatr Oncol Nurs. 1996 Jul;13(3):150-2. doi: 10.1177/104345429601300308. J Pediatr Oncol Nurs. 1996. PMID: 8755444 Review. No abstract available.
Busulfan in hematopoietic stem cell transplant setting.
McCune JS, Holmberg LA. McCune JS, et al. Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):957-69. doi: 10.1517/17425250903107764. Expert Opin Drug Metab Toxicol. 2009. PMID: 19611402 Review.
Busulfan is commonly used in HCT as it is toxic to the marrow. Busulfan is available as oral or i.v. formulation. The most common significant toxicity of busulfan is sinusoidal obstruction syndrome. Even with the introduction of i.v. busulfan, variabil …
Busulfan is commonly used in HCT as it is toxic to the marrow. Busulfan is available as oral or i.v. formulation. The most com …
Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.
Lawson R, Staatz CE, Fraser CJ, Hennig S. Lawson R, et al. Clin Pharmacokinet. 2021 Jan;60(1):17-51. doi: 10.1007/s40262-020-00947-2. Epub 2020 Oct 30. Clin Pharmacokinet. 2021. PMID: 33128207 Review.
One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL. Patient weight, age and GSTA1 genotype are important covariates to consider when individualising busulfan therapy. ...Standardised monitoring of busu …
One study observed increased sinusoidal obstructive syndrome with maximum busulfan concentration > 1.88 ng/mL. Patient weight, age …
Busulfan use in hematopoietic stem cell transplantation: pharmacology, dose adjustment, safety and efficacy in adults and children.
Krivoy N, Hoffer E, Lurie Y, Bentur Y, Rowe JM. Krivoy N, et al. Curr Drug Saf. 2008 Jan;3(1):60-6. doi: 10.2174/157488608783333899. Curr Drug Saf. 2008. PMID: 18690982 Review.
Busulfan has a very narrow therapeutic index, and acute toxicity may be related to absorption and disposition of the drug and metabolites. ...Busulfan therapeutic drug monitoring and dose-adjustment should be performed in specialized laboratories staffed by well-tra …
Busulfan has a very narrow therapeutic index, and acute toxicity may be related to absorption and disposition of the drug and metabol …
Personalized busulfan and treosulfan conditioning for pediatric stem cell transplantation: the role of pharmacogenetics and pharmacokinetics.
ten Brink MH, Zwaveling J, Swen JJ, Bredius RG, Lankester AC, Guchelaar HJ. ten Brink MH, et al. Drug Discov Today. 2014 Oct;19(10):1572-86. doi: 10.1016/j.drudis.2014.04.005. Epub 2014 Apr 16. Drug Discov Today. 2014. PMID: 24747172 Review.
Busulfan- and treosulfan-based conditionings are the cornerstone of pediatric allogeneic hematopoietic stem cell transplantation (HSCT). Although both drugs are alkylating agents, their mechanisms of action, pharmacokinetics (PK) and toxicity profiles are different. Experi …
Busulfan- and treosulfan-based conditionings are the cornerstone of pediatric allogeneic hematopoietic stem cell transplantation (HSC …
Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
Vassal G. Vassal G. Anticancer Res. 1994 Nov-Dec;14(6A):2363-70. Anticancer Res. 1994. PMID: 7825973 Review.
High-dose busulfan is used in conditioning regimens before allogeneic or autologous bone marrow transplantation (BMT) in adults and children. ...The definition of a therapeutic window according to the disease and the type of BMT, along with the development of iv-busulfa …
High-dose busulfan is used in conditioning regimens before allogeneic or autologous bone marrow transplantation (BMT) in adults and c …
Busulfan disposition in children.
Grochow LB, Krivit W, Whitley CB, Blazar B. Grochow LB, et al. Blood. 1990 Apr 15;75(8):1723-7. Blood. 1990. PMID: 2328321 Free article.
Children receive busulfan orally as part of myeloablative therapy before bone marrow transplantation for malignant and nonmalignant conditions. ...The apparent volume of distribution (assuming complete bioavailability) ranged from 0.28 to 3.53 L/kg (1.42 +/- 0.86), which i …
Children receive busulfan orally as part of myeloablative therapy before bone marrow transplantation for malignant and nonmalignant c …
Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program.
McCune JS, Punt AM, Yeh RF, Dupuis LL, Kweekel DM, Franssen EJF, Ritchie JC, van Maarseveen E, Huitema ADR. McCune JS, et al. Ther Drug Monit. 2021 Oct 1;43(5):657-663. doi: 10.1097/FTD.0000000000000862. Ther Drug Monit. 2021. PMID: 33675302
BACKGROUND: Personalizing busulfan doses to target a narrow plasma exposure has improved the efficacy and lowered the toxicity of busulfan-based conditioning regimens used in hematopoietic cell transplant. Regional regulations guide interlaboratory proficiency testi …
BACKGROUND: Personalizing busulfan doses to target a narrow plasma exposure has improved the efficacy and lowered the toxicity of …
Busulfan clearance does not predict the development of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation.
Salman B, Al-Khabori M, Al-Huneini M, Al-Rawas A, Dennison D, Al-Za'abi M. Salman B, et al. Int J Hematol. 2020 Aug;112(2):210-216. doi: 10.1007/s12185-020-02891-0. Epub 2020 May 28. Int J Hematol. 2020. PMID: 32468179
All patients who received dose-targeted busulfan-containing conditioning were included. Target steady-state concentration (Css) was 800-900 ng/ml. ...Targeting busulfan Css into narrow therapeutic range may have accounted for the findings. ...
All patients who received dose-targeted busulfan-containing conditioning were included. Target steady-state concentration (Css) was 8 …
7,538 results

Searches related to "busulfan"